tbuckley/cabot-search huggingface dataset:
Germline <i>SUFU</i> mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis
Authors: Léa Guerrini-Rousseau, Christelle Dufour, Pascale Varlet, Julien Masliah-Planchon, Franck Bourdeaut, Marine Guillaud-Bataille, Rachid Abbas, Anne-Isabelle Bertozzi, Fanny Fouyssac, Sophie Huybrechts, Stéphanie Puget, Brigitte Bressac-De Paillerets, Olivier Caron, Nicolas Sevenet, Marina Dimaria, Sophie Villebasse, Olivier Delattre, Dominique Valteau-Couanet, Jacques Grill, Laurence Brugières
Journal: Neuro-Oncology (2017)

Germline mutations of suppressor of fused homolog (SUFU) predispose to sonic hedgehog (SHH) medulloblastoma. Germline SUFU mutations have been reported in nevoid basal cell carcinoma syndrome (NBCCS), but little is known about the cancer risk and clinical spectrum.We performed a retrospective review of all patients with medulloblastoma and a germline SUFU mutation in France.Twenty-two patients from 17 families were identified with medulloblastoma and a germline SUFU mutation (median age at diagnosis: 16.5 mo). Macrocrania was present in 20 patients, but only 5 met the diagnostic criteria for NBCCS. Despite treatment with surgery and chemotherapy, to avoid radiotherapy in all patients except one, the outcome was worse than expected for SHH medulloblastoma, due to the high incidence of local relapses (8/22 patients) and second malignancies (n = 6 in 4/22 patients). The 5-year progression-free survival and overall survival rates were 42% and 66%. Mutations were inherited in 79% of patients, and 34 additional SUFU mutation carriers were identified within 14 families. Medulloblastoma penetrance was incomplete, but higher than in Patched 1 (PTCH1) mutation carriers. Besides medulloblastoma, 19 other tumors were recorded among the 56 SUFU mutation carriers, including basal cell carcinoma (BCC) in 2 patients and meningioma in 3 patients.Germline SUFU mutations strongly predispose to medulloblastoma in the first years of life, with worse prognosis than usually observed for SHH medulloblastoma. The clinical spectrum differs between SUFU and PTCH1 mutation carriers, and BCC incidence is much lower in SUFU mutation carriers. The optimal treatment of SUFU mutation-associated medulloblastoma has not been defined.
Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience
Authors: Alessandra Fornaro, Iacopo Olivotto, Luigi Rigacci, Mauro Ciaccheri, Benedetta Tomberli, Cecilia Ferrantini, Raffaele Coppini, Francesca Girolami, Francesco Mazzarotto, Marco Chiostri, Massimo Milli, Niccolò Marchionni, Gabriele Castelli
Journal: European Journal of Heart Failure (2017)
Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes
Authors: Yun Yun Go, Tadafumi Sugimoto, Heerajnarain Bulluck, Sanchalika Acharyya, John Carson Allen, Shaw Yang Chia, Fazlur Rehman Jaufeerally, David Sim, Tiong Keng Lim, Reginald Liew, Carolyn S.P. Lam
Journal: European Journal of Heart Failure (2017)
Phase Ic trial of intralesional OrienX010 oncolytic viral therapy into liver metastases among melanoma patients
Authors: C. Cui, B. Lian, Z. Chi, L. Si, X. Sheng, T. Bixia, L. Mao, X. Wang, X. Yan, S. Li, L. Zhou, X. Bai, J. Guo
Journal: Annals of Oncology (2017)
Abstract 13458: Caspase Recruitment Domain-Containing Protein 9 Deficiency Mitigates Obesity-Induced Cardiac Dysfunction
Authors: Li Cao, Xing Qin, Tiantian Zheng, Sreejayan Nair, Jun Ren, Guanglong He
Journal: Circulation (2015)

Obesity has become an epidemic and is associated with cardiovascular anomalies. Obesity-induced low-grade chronic inflammation and macrophage infiltration into the heart plays a critical role in the development of cardiac dysfunction. Because the adaptor protein caspase recruitment domain-containing protein 9 (CARD9) regulates the innate immunity in macrophages via activation of pro-inflammatory cytokines, we hypothesized that CARD9 mediates chronic inflammation and plays a detrimental role in obesity-associated cardiac dysfunction. Male C57BL/6 wild-type (WT) and CARD9 knockout (CARD9-/-) mice were fed normal chow (ND, 12% fat) or a Western diet (WD, 45% fat) for 5 months starting at 4 weeks of age. At the end of 5-month WD feeding, cardiac geometry and function were evaluated using echocardiography. Immunofluorescence assay was performed to detect macrophage infiltration in the heart. Heart tissue homogenates, plasma, and supernatants from cultured macrophages were collected to measure the activities of pro-inflammatory cytokines by ELISA kits. Western immunoblotting analyses were performed on isolated peritoneal macrophages and heart tissue to dissect the pro-inflammatory signaling pathways. WD feeding induced insulin resistance and glucose intolerance in the WT mice and the effects were attenuated in the CARD9-/- mice. Myocardial fractional shortening and ejection fraction were significantly compromised in the WD-fed WT mice and CARD9 knockout preserved cardiac function. CARD9 knockout also significantly decreased the number of infiltrated macrophages in the heart. In addition, myocardium-, plasma- and macrophage-derived cytokines IL-6, IL-1β and TNFα were attenuated in the CARD9-/- mice compared to the WT mice. WD feeding resulted in increased protein phosphorylation levels of p38 MAPK in the heart and macrophages which were suppressed in the CARD9-/- mice. Taken together, these results suggest that CARD9 knockout ameliorates obesity-induced cardiac dysfunction, potentially through reduction of macrophage infiltration and suppression of p38 MAPK phosphorylation in the heart.
P2.07-002 Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors
Authors: M. Nishino, A. Adeni, H. Hatabu, C. Lydon, T. Hida, F.S. Hodi, M. Awad
Journal: Journal of Thoracic Oncology (2017)
Letter to the editor: Livestock-associated meticillin-resistant Staphylococcus aureus (LA-MRSA), Austria, 2013
Authors: Werner Ruppitsch, Stefanie Monschein, Sarah Lepuschitz, Franz Allerberger, Burkhard Springer
Journal: Eurosurveillance (2017)

Preview this article: Letter to the editor: Livestock-associated meticillin-resistant Staphylococcus aureus (LA-MRSA), Austria, 2013, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/22/46/eurosurv-22-46-6-1.gif
Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis
Authors: Lewis R. Roberts, Claude B. Sirlin, Feras Zaiem, Jehad Almasri, Larry J. Prokop, Julie K. Heimbach, M. Hassan Murad, Khaled Mohammed
Journal: Hepatology (2017)

Multiphasic computed tomography (CT) and magnetic resonance imaging (MRI) are both used for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. To determine if there is a relative diagnostic benefit of one over the other, we synthesized evidence regarding the relative performance of CT, extracellular contrast–enhanced MRI, and gadoxetate‐enhanced MRI for diagnosis of HCC in patients with cirrhosis. We also assessed whether liver biopsy versus follow‐up with the same versus alternative imaging is best for CT‐indeterminate or MRI‐indeterminate liver nodules in patients with cirrhosis. We searched multiple databases from inception to April 27, 2016, for studies comparing CT with extracellular contrast–enhanced MRI or gadoxetate‐enhanced MRI in adults with cirrhosis and suspected HCC. Two reviewers independently selected studies and extracted data. Of 33 included studies, 19 were comprehensive, while 14 reported sensitivity only. For all tumor sizes, the 19 comprehensive comparisons showed significantly higher sensitivity (0.82 versus 0.66) and lower negative likelihood ratio (0.20 versus 0.37) for MRI over CT. The specificities of MRI versus CT (0.91 versus 0.92) and the positive likelihood ratios (8.8 versus 8.1) were not different. All three modalities performed better for HCCs ≥2 cm. Performance was poor for HCCs &lt;1 cm. No studies examined whether adults with cirrhosis and an indeterminate nodule are best evaluated using biopsy, repeated imaging, or alternative imaging. Concerns about publication bias, inconsistent study results, increased risk of bias, and clinical factors precluded support for exclusive use of either gadoxetate‐enhanced or extracellular contrast–enhanced MRI over CT. Conclusion: CT, extracellular contrast–enhanced MRI, or gadoxetate‐enhanced MRI could not be definitively preferred for HCC diagnosis in patients with cirrhosis; in patients with cirrhosis and an indeterminate mass, there were insufficient data comparing biopsy to repeat cross‐sectional imaging or alternative imaging. (H epatology 2018;67:401‐421).
The Value-Based Payment Modifier: Program Outcomes and Implications for Disparities
Authors: Eric T. Roberts, Alan M. Zaslavsky, J. Michael McWilliams
Journal: Annals of Internal Medicine (2017)

Background: When risk adjustment is inadequate and incentives are weak, pay-for-performance programs, such as the Value-Based Payment Modifier (Value Modifier [VM]) implemented by the Centers for Medicare & Medicaid Services, may contribute to health care disparities without improving performance on average. Objective: To estimate the association between VM exposure and performance on quality and spending measures and to assess the effects of adjusting for additional patient characteristics on performance differences between practices serving higher-risk and those serving lower-risk patients. Design: Exploiting the phase-in of the VM on the basis of practice size, regression discontinuity analysis and 2014 Medicare claims were used to estimate differences in practice performance associated with exposure of practices with 100 or more clinicians to full VM incentives (bonuses and penalties) and exposure of practices with 10 or more clinicians to partial incentives (bonuses only). Analyses were repeated with 2015 claims to estimate performance differences associated with a second year of exposure above the threshold of 100 or more clinicians. Performance differences were assessed between practices serving higher- and those serving lower-risk patients after standard Medicare adjustments versus adjustment for additional patient characteristics. Setting: Fee-for-service Medicare. Patients: Random 20% sample of beneficiaries. Measurements: Hospitalization for ambulatory care–sensitive conditions, all-cause 30-day readmissions, Medicare spending, and mortality. Results: No statistically significant discontinuities were found at the threshold of 10 or more or 100 or more clinicians in the relationship between practice size and performance on quality or spending measures in either year. Adjustment for additional patient characteristics narrowed performance differences by 9.2% to 67.9% between practices in the highest and those in the lowest quartile of Medicaid patients and Hierarchical Condition Category scores. Limitation: Observational design and administrative data. Conclusion: The VM was not associated with differences in performance on program measures. Performance differences between practices serving higher- and those serving lower-risk patients were affected considerably by additional adjustments, suggesting a potential for Medicare's pay-for-performance programs to exacerbate health care disparities. Primary Funding Source: The Laura and John Arnold Foundation and National Institute on Aging.
Abstract 16144: Death Associated Protein Kinase Mediates Myofibril Degeneration and Myocyte Apoptosis Induced by Beta-adrenergic Receptors
Authors: Xinji Guo, Bahman Hooshdaran, Khadija Rafiq, Hang Xi, Mikhail Kolpakov, Shaojun Liu, Xiaoying Zhang, Xiongwen Chen, Steven R Houser, Walter J Koch, Abdelkarim Sabri
Journal: Circulation (2016)

Background: Death associated protein kinase (DAPK) is a novel Ca2+/calmodulin-regulated serine/threonine kinase that regulates cytoskeletal dynamics and cell death. Because chronic activation of Ca...
Dynamic and direct pathogen load surveillance to monitor disease progression and therapeutic efficacy in central nervous system infection using a novel semi-quantitive sequencing platform
Authors: Jing-Wen Ai, Hao-Cheng Zhang, Peng Cui, Bin Xu, Yan Gao, Qi Cheng, Tao Li, Honglong Wu, Wen-Hong Zhang
Journal: Journal of Infection (2017)
Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease
Authors: Kathy S. Wang, Haesook T. Kim, Sarah Nikiforow, Alexander T. Heubeck, Vincent T. Ho, John Koreth, Edwin P. Alyea, Philippe Armand, Bruce R. Blazar, Robert J. Soiffer, Joseph H. Antin, Corey S. Cutler, Jerome Ritz
Journal: Blood (2017)
Abstract 13113: Identification of Novel Copper-dependent Wound Repair Mechanism: Role of Copper Transport Protein Antioxidant 1
Authors: Archita Das, Gin-Fu Chen, Ha Won Kim, Sudhahar Varadarajan, Seock-Won Youn, Jay Yang, Lydia Finney, Masuko Ushio-Fukai, Tohru Fukai
Journal: Circulation (2015)

Copper (Cu) facilitates wound healing and angiogenesis with unknown mechanism. Bioavailability of Cu is controlled by transport-proteins, including cytosolic Cu-chaperone Atox1, which is required for activation of secretory Cu enzymes. Atox1 also functions as a Cu-dependent transcription factor, but its role in wound healing is unknown. Using mouse skin puncture model, here we show that Atox1 protein (8-fold) and Cu-level (by X-ray Fluorescence Microscopy; 2.5-fold) were increased in wounding tissue in wild type (WT) mice at day 7 when Atox1 was localized in nucleus of dermal endothelial cells (ECs) as well as cytosol of epidermal cells, granulation tissue. Furthermore, topical Cu treatment enhanced (20% vs PBS), but specific Cu chelator BCS reduced wound repair in WT mice. Importantly, Atox1 knockout (KO) mice showed abolished topical Cu-induced wound repair or impaired endogenous wound healing vs. WT mice, which was associated with decreased angiogenesis (CD31+, 45% ), proliferation (BrdU+, 60%), ROS-production (DHE+), collagen formation (Masson's Trichrome), and infiltration of macrophage (Mac3+,40%) which secrets angiogenic cytokines VEGF and SDF-1α. Mechanistically, Atox1KO mice exhibited reduced wounding-induced expression of Atox1 target proteins such as p47phox NADPH oxidase and cyclin D1 as well as extracellular matrix secretory Cu-enzyme lysyl oxidase activity. Finally, bone marrow (BM) transplantation revealed that Atox1 in both BM and tissue resident cells are required for wound repair. Consistently, Atox1 protein and Cu were markedly increased in WT-BM tissue after wounding. Impaired wound healing in Atox1 KO mice was rescued by both Atox1-gene transfer and WT-BM topical treatment in wound tissues. In summary, Atox1 senses Cu to accelerate wound healing/repair by promoting angiogenesis, inflammatory cell recruitment, proliferation, extracellular matrix maturation as well as BM cell function. Taken together, Cu-Atox1-based therapy may represent a novel therapeutic strategy to promote dermal wound healing and tissue regeneration.
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Authors: Carlo Genova, Mark A. Socinski, Rebecca R. Hozak, Gu Mi, Raffael Kurek, Javad Shahidi, Luis Paz-Ares, Nick Thatcher, Christopher J. Rivard, Marileila Varella- Garcia, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
Work disability in gout: a population-based case–control study
Authors: Valgerdur Sigurdardottir, Panagiota Drivelegka, Anna Svärd, Lennart T H Jacobsson, Mats Dehlin
Journal: Annals of the Rheumatic Diseases (2017)

Objectives To examine the extent and cost of work disability among patients with gout compared with matched population controls and to analyse predictors of work disability. Methods A regional cohort study using data from Swedish national and regional registries from January 2000 through December 2012, including 4571 patients with gout of working age, with a first recorded diagnosis of gout in the years 2003–2009 and 22 482 population controls, matched by age, sex and place of residence. Differences in baseline characteristics (educational level, income, previous employment and comorbidities) and the number of work-loss days (absenteeism) due to sick leave and disability pension for 3 years after identification were calculated. Predictors for new-onset work absenteeism (&gt;90 days/year) in a subset were determined by conditional logistic regression. Results Patients with gout (median age 53 years) had significantly more comorbidities, lower income and lower level of education than matched controls. The average work absentee rate during the 3-year follow-up period was higher among patients with gout than controls, 22% and 14%, respectively (P&lt;0.0001). New-onset absenteeism was in multivariate analyses significantly predicted by gout (OR 1.47; 95% CI 1.23 to 1.75). Other variables independently related to new-onset absenteeism were education ≤12 years, previous unemployment and history of sick leave, in addition to several comorbidities (renal disease, cardiovascular disease, alcohol abuse and obesity). Conclusions Gout is associated with substantially higher work absenteeism and costs for society due to productivity loss, after adjusting for associated comorbidities and socioeconomic differences. Whether more intensive treatment of gout is cost-effective needs to be addressed in future studies.
Octava Reunión internacional del Grupo de trabajo europeo de difteria y de la Red europea de vigilancia de la difteria – Junio de 2004 : se necesitan mejoras para el control de la difteria en la Región Europea
Authors: A De Zoysa, A Efstratiou
Journal: Eurosurveillance (2004)

El octavo encuentro internacional del Grupo de trabajo europeo en materia de difteria (ELWGD) y de la Red europea de vigilancia de la difteria (DIPNET) tuvo lugar y fue co-organizado con la Oficina regional para Europa de la OMS en Copenhague, Dinamarca, en Junio de 2004. El articulo siguiente presenta una actualizacion internacional de los progresos clinicos, epidemiologicos y microbiologicos de la difteria en Europa, tal y como fueron presentados durante la reunion. El conjunto de estos datos pone de manifiesto la necesidad de mejorar la cobertura vacunal, fortalecer la vigilancia y los estudios epidemiologicos para mantener el control de la difteria en la Region Europea.
In stable CVD, rivaroxaban plus aspirin reduced CV events and increased bleeding compared with aspirin alone
Authors: Steven Borzak
Journal: Annals of Internal Medicine (2017)

ACP Journal Club21 November 2017In stable CVD, rivaroxaban plus aspirin reduced CV events and increased bleeding compared with aspirin aloneSteven Borzak, MDSteven Borzak, MDUniversity of Miami Miller School of Medicine, Florida Atlantic University, Atlantis, Florida, USA (S.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-10-052 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationEikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017. [Epub ahead of print]. https://pubmed.ncbi.nlm.nih.gov/28844192Clinical Impact RatingsGIM/FP/GP: Cardiology: Hematology: References1 Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423-34. [PMID: 27959713] Google Scholar2 Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. [PMID: 22077192] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Miami Miller School of Medicine, Florida Atlantic University, Atlantis, Florida, USA (S.B.)This article was published at Annals.org on 7 November 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIn AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplateletGaetano Santulli, MD 21 November 2017Volume 167, Issue 10Page: JC52KeywordsAnticoagulantsAntiplatelet therapyAspirinHemorrhageHemorrhagic strokeMyocardial infarctionNumber needed to treatStable coronary artery diseaseStrokeVascular diseases ePublished: 21 November 2017 Issue Published: 21 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Low dietary fiber intake increases<i>Collinsella</i>abundance in the gut microbiota of overweight and obese pregnant women
Authors: Luisa F. Gomez-Arango, Helen L. Barrett, Shelley A. Wilkinson, Leonie K. Callaway, H. David McIntyre, Mark Morrison, Marloes Dekker Nitert
Journal: Gut Microbes (2017)

The gut microbiota contributes to the regulation of glucose metabolism in pregnancy. Abundance of the genus Collinsella is positively correlated with circulating insulin; however, it is unclear what determines Collinsella abundance. This study aims to validate the correlation between Collinsella and insulin and to elucidate if macronutrient intake alters Collinsella abundance and gut microbiota composition. Gut microbiota profiles were assessed by 16S rRNA sequencing in 57 overweight and 73 obese pregnant women from the SPRING (Study of PRobiotics IN Gestational diabetes) trial at 16 weeks gestation and correlated with metabolic hormone levels and macronutrient intake. Gut microbiota composition in the top and bottom 10% of dietary fiber intake was evaluated through network analysis. Collinsella abundance correlated positively with circulating insulin (rho = 0.30, p = 0.0006), independent of maternal BMI, but negatively with dietary fiber intake (rho = -0.20, p = 0.025) in this cohort. Low dietary fiber intake was associated with a gut microbiota favoring lactate fermentation while high fiber intake promotes short-chain fatty acid-producing bacteria. Low dietary fiber may enable overgrowth of Collinsella and alter the overall fermentation pattern in gut microbiota. This suggests that dietary choices during pregnancy can modify the nutritional ecology of the gut microbiota, with potential deleterious effects on the metabolic and inflammatory health of the host.ANZCTR 12611001208998, registered 23/11/2011.
Randomized phase II study of TJ-54 (Yokukansan) for postoperative delirium in gastrointestinal and lung malignancy patients
Authors: J. Morita, T. Aoyama, N. Sugano, T. Sato, S. Amano, T. Nagashima, Y. Ishikawa, M. Taguri, T. Yamanaka, Y. Yamamoto, T. Oshima, N. Yukawa, Y. Rino, M. Masuda
Journal: Annals of Oncology (2017)